Cargando…

Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development

BACKGROUND: SLFN11 has recently been reported to execute cancer cells harboring replicative stress induced by DNA damaging agents. However, the roles of SLFN11 under physiological conditions remain poorly understood. Germinal center B-cells (GCBs) undergo somatic hypermutations and class-switch reco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moribe, Fumiya, Nishikori, Momoko, Takashima, Tsuyoshi, Taniyama, Daiki, Onishi, Nobuyuki, Arima, Hiroshi, Sasanuma, Hiroyuki, Akagawa, Remi, Elloumi, Fathi, Takeda, Shunichi, Pommier, Yves, Morii, Eiichi, Takaori-Kondo, Akifumi, Murai, Junko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846023/ https://www.ncbi.nlm.nih.gov/pubmed/33513156 http://dx.doi.org/10.1371/journal.pone.0237554

Ejemplares similares

The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B‐cell lymphoma and enhances T‐cell recruitment
por: Yuan, Hepei, et al.
Publicado: (2021)

SLFN11’s surveillance role in protein homeostasis
por: Murai, Yasuhisa, et al.
Publicado: (2022)

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
por: Murai, Junko, et al.
Publicado: (2016)

Concurrent development of small lymphocytic lymphoma and lung cancer: A report of two cases and a review of the literature
por: Nakao, Kensuke, et al.
Publicado: (2023)

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
por: Ballestrero, Alberto, et al.
Publicado: (2017)

SPDR-4 SLFN11 RENDERS MEDULLOBLASTOMA SENSITIVE TO DNA DAMAGE CHEMOTHERAPIES
por: Nakata, Satoshi, et al.
Publicado: (2022)

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2020)

SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
por: Jo, Ukhyun, et al.
Publicado: (2021)

Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response
por: Alvi, Erin, et al.
Publicado: (2023)

T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy
por: Wada, Fumiya, et al.
Publicado: (2022)

EBV‐associated lymphoproliferative disorder in a patient with X‐linked severe combined immunodeficiency with multiple reversions of an IL2RG mutation in T cells
por: Wada, Fumiya, et al.
Publicado: (2020)

A sporadic case of CTLA4 haploinsufficiency manifesting as Epstein–Barr virus-positive diffuse large B-cell lymphoma
por: Yuan, Hepei, et al.
Publicado: (2021)

A case of neurolymphomatosis caused by follicular lymphoma successfully treated with bendamustine
por: Umeda, Masayuki, et al.
Publicado: (2015)

Persistence of a t(11;14)‐positive clone in a patient with mantle cell lymphoma for 20 years
por: Otsuka, Yasuyuki, et al.
Publicado: (2017)

Relapse of follicular lymphoma arising from a non‐t(14;18) clone
por: Otsuka, Yasuyuki, et al.
Publicado: (2020)

Intravascular clusters of T cells following chimeric antigen receptor T cell therapy
por: Nakamura, Naokazu, et al.
Publicado: (2022)

Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase
por: Garvie, Colin W., et al.
Publicado: (2021)

Mechanistic understanding of human SLFN11
por: Metzner, Felix J., et al.
Publicado: (2022)

SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression
por: Fischietti, Mariafausta, et al.
Publicado: (2022)

SLFN14 gene mutations associated with bleeding
por: Stapley, Rachel J., et al.
Publicado: (2019)

Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T‐cell therapy
por: Nakamura, Naokazu, et al.
Publicado: (2022)

Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
por: Jo, Tomoyasu, et al.
Publicado: (2023)

Expression of Tim‐1 in primary CNS lymphoma
por: Kishimoto, Wataru, et al.
Publicado: (2016)

Ribosome dysfunction underlies SLFN14-related thrombocytopenia
por: Ver Donck, Fabienne, et al.
Publicado: (2023)

Recurrent Epstein-Barr Virus-positive (EBV+) Primary Central Nervous System Lymphoma (PCNSL) in a Patient with Clinical Features of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS)
por: Nagano, Masahiro, et al.
Publicado: (2019)

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
por: Nogales, Vanesa, et al.
Publicado: (2015)

Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum‐based chemotherapy
por: Taniyama, Daiki, et al.
Publicado: (2021)

SLFN5 promotes reversible epithelial and mesenchymal transformation in ovarian cancer
por: Xu, Qiao Ping, et al.
Publicado: (2023)

Post‐transplant Lymphoproliferative Disorders After Liver Transplantation: A Retrospective Cohort Study Including 1954 Transplants
por: Tajima, Tetsuya, et al.
Publicado: (2021)

Characterization of Novel Ribosome-Associated Endoribonuclease SLFN14 from Rabbit Reticulocytes
por: Pisareva, Vera P., et al.
Publicado: (2015)

Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma
por: Zoppoli, Gabriele, et al.
Publicado: (2015)

Loss of T-cell quiescence by targeting Slfn2 prevents the development and progression of T-ALL
por: Goldshtein, Aviya, et al.
Publicado: (2016)

Modulation of SLFN11 induces changes in DNA Damage response in breast cancer
por: Raynaud, Christophe Michel, et al.
Publicado: (2023)

Heterogeneous Breakpoints on the Immunoglobulin Genes Are Involved in Fusion with the 5′ Region of BCL2 in B‐Cell Tumors
por: Yonetani, Noboru, et al.
Publicado: (2001)

SLAM family member 8 is expressed in and enhances the growth of anaplastic large cell lymphoma
por: Sugimoto, Akihiko, et al.
Publicado: (2020)

Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma
por: Yamasaki-Morita, Makiko, et al.
Publicado: (2022)

Role of the novel endoribonuclease SLFN14 and its disease-causing mutations in ribosomal degradation
por: Fletcher, Sarah J., et al.
Publicado: (2018)

Novel SLFN14 mutation associated with macrothrombocytopenia in a patient with severe haemorrhagic syndrome
por: Polokhov, Dmitrii, et al.
Publicado: (2023)

PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)

Bortezomib Against Refractory Antibody-Mediated Rejection After ABO-Incompatible Living-Donor Liver Transplantation: Dramatic Effect in Acute-Phase?
por: Tajima, Tetsuya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fa8itg6h7f8pck0q9q2hhgabsq